TABLE 3.
Hazard ratios and 95% confidence intervals for cause-specific ovarian cancer mortality by hormone regimen and duration of use among women with ovarian cancer.
| Any Hormone Therapy | Estrogen alone | Estrogen+Progestin only | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. Censored |
No. of Deaths |
HR (95% CI)a | HR (95% CI)b | No. Censored |
No. of Deaths |
HR (95% CI)b | No. Censored |
No. of Deaths |
HR (95% CI)b | |
| Never use | 291 | 206 | 1.00 (Referent) | 1.00 (Referent) | 291 | 206 | 1.00 (Referent) | 291 | 206 | 1.00 (Referent) |
| Ever use | 155 | 99 | 1.03 (0.80–1.34) | 1.10 (0.85–1.43) | 99 | 51 | 0.99 (0.71–1.37) | 34 | 35 | 1.25 (0.85–1.86) |
| Current | 135 | 80 | 1.04 (0.78–1.37) | 1.09 (0.82–1.45) | 86 | 41 | 0.96 (0.67–1.39) | 28 | 28 | 1.28 (0.82–1.99) |
| Former | 20 | 19 | 1.03 (0.64–1.67) | 1.15 (0.70–1.89) | 13 | 10 | 1.17 (0.77–1.78) | 6 | 7 | 1.18 (0.52–2.65) |
| Duration of use (years) | ||||||||||
| <5 | 96 | 53 | 0.99 (0.72–1.36) | 1.12 (0.81–1.55) | 67 | 29 | 1.17 (0.77–1.78) | 18 | 19 | 1.13 (0.68–1.88) |
| ≥5 | 59 | 46 | 1.09 (0.78–1.53) | 1.08 (0.76–1.53) | 32 | 22 | 0.80 (0.50–1.28) | 16 | 16 | 1.40 (0.81–2.43) |
a
Adjusted for age at diagnosis, study state, and year of interview.
b
Additionally adjusted for body mass index, oral contraceptive use, parity, menopausal status, and stage.